Goldman Advisors Group Acts as Consultant on Vital Neuro’s Initial Coin Offering - The World’s first Neurotechnology Token with Preferred Equity Reward:


Illinois, Michigan, Oct. 02, 2018 (GLOBE NEWSWIRE) -- (

Vital Neuro Launches World’s First Neurotechnology ICO with Preferred Equity Reward

NEW YORK - Vital Neuro ( is pleased to announce the launch of the Neuros Token Security Token Sale, the world’s first neurotechnology ICO with Preferred Equity Reward giving token holders preferred equity in the Company. 

Vital Neuro subsidiary Neuro Token opened its global Initial Coin Offering (ICO) of Neuros Token to accredited investors today on partner Start Engine’s platform. (

Vital Neuro will offer Token holders with a preferred equity reward in the Company pursuant to Simple Agreements for Future Equity (SAFE) in three offerings in accordance with Rule 506 (c) of Regulation D of the Securities Act. Prior to this offering, Vital has raised $675,000 in a non-preferred private offering.

During the period which commenced on September 14, 2018, and which is anticipated to run through October 31, 2018 (Pre-Sale Offering 1), Neuro Token will enter into SAFEs with accredited investors for a 70% discount at a price of $1.50 per token with a total number of 7,000,000 issuable tokens. 

During the period which is expected to commence on October 31, 2018 anticipated to run through December 31, 2018 (Pre-Sale Offering 2), Neuro Token will enter into SAFEs with accredited investors for a 40% discount at a price of $3.00 per token with a total number of 7,000,000 issuable tokens. 

During the period which is expected to commence on January 1, 2019 and is anticipated to run through March 31, 2019 (ICO Offering 3), Neuro Token will enter into SAFE’s with accredited investors for a price of $5.00 per token with a total number of 3,650,000 issuable tokens. 

The Pre-Sale Period Offering 1 and Subsequent Offering Periods may each be extended or shortened at the Company’s sole discretion. Any change to such dates will be announced by press release or other available means of notifying purchaser.  

Vital Neuro CEO Q Saeed said: “Vital Neuro is proud to be the neurotechnology leading enterprise to embrace the crypto revolution.  Vital Neuro today opens the Neuros Token ICO. Beginning with the ‘Pre-Sale Offering 1’ round, I am confident that accredited investors from around the globe will recognize the value and potential of our pioneering stress reduction service for companies, tapping a $250 billion+ global opportunity in the neuroscience market. We believe the market Vital is defining and segmenting will transform into a worldwide service for any human experiencing stress.”

Prior to the ICO Vital Neuro closed $675,000 in a Regulation D Private Sale Non-Token Equity Round. Proceeds have funded ongoing R&D allowing the company to complete the working prototype of its neuroscience-based stress reduction service for enterprise companies.

Vital Neuro Chief Product Officer Alex Doman added, “the last two years have been an exciting period of innovation for our team, creating an affordable subscription service that addresses the massive issue of workplace stress and burnout which costs US businesses $30 billion yearly in lost workdays alone. Our exclusive Leonardo Smart Cloud Service powered by AWS, native iOS app, and wireless Vital Smart Headphone provides real time monitoring of biosignals through dry EEG sensors. Vital’s Leonardo is a gamechanger; monitoring stress levels in real time and delivering scientifically designed sound and music through sleek, wireless, high-fidelity headphones, reducing stress in 15-minute sessions personalized to the employee.”

The Neuros Token launch will allow a hard cap of 19,238,500 coins in circulation with investors holding 91.8%, leaving less than 9% of all outstanding tokens being retained by Vital Neuro. Each Token corresponds to an equal value of Vital Neuro’s equity, pro-rata, totaling 20% of the entire Company. Purchase of 5,000 or more Tokens qualifies the holder to participate in the Company’s Discretionary Dividend Program. Complete details about the Neuros Token offering are available in the Vital Neuro whitepaper. 

About Vital Neuro

Vital Neuro, Inc. is at the forefront of neurotechnology powering neuroscience for workplace stress reduction. Vital’s innovative science-based platform offers a solution to employee stress and burnout through stress reduction as a service. A Mobile SaaS for enterprise customers allows employers to provide their team members with enjoyable, neuroscience-based stress reduction sessions built on real time monitoring of personal biosignals. The results included improved job satisfaction, higher productivity, lower employee turnover, and increased profitability.

About Neuro Token     

Neuro Token, Inc., is a subsidiary of Vital Neuro, Inc., providing its innovative cryptocurrency element Neuros Token to its overall company portfolio.

About Start Engine

StartEngine is the leading regulated ICO 2.0 platform in the U.S., connecting everyday investors with tomorrow’s progressive companies. Utilizing its expertise in regulated exempt offerings under the JOBS Act, StartEngine has raised capital for more than 150 companies and has nearly 140,000 users on its platform. Based in Los Angeles, the company was created in 2014 by Howard Marks, co-founder of Activision, and Ron Miller. StartEngine is committed to revolutionizing the ways companies raise capital and to helping entrepreneurs achieve their dreams.

About Goldman Advisors Group

Goldman Advisors Group is a boutique consulting firm that advises and assists clients with many complex business matters including mergers and acquisitions, spin-offs, corporate restructuring, business plans and planning, start-up creation and funding, due diligence process, public and private market funding, business and litigation strategy, financial structuring, private placements and venture capital, contractual diligence, and all aspects of corporate marketing.

Forward Looking Statements: Statements which are not historical facts contained in this release are forward looking statements, such as "leading enterprise" that involve risks and uncertainties, including but not limited to, the effect of economic conditions, the impact of competition, the results of financing efforts, changes in consumers' preferences and trends. The words "confident," "pioneering," and "transform,” “gamechanger,” “forefront,” “innovative,” and similar expressions, and offering defined dates and amount identify forward-looking statements, which speak only to the date the statement was made. Risk factors exist and may change the potential outcome. Such factors include, but are not limited to, the timing and extent of changes in market conditions and prices for natural gas and oil; thereby future events and actual results may differ materially from those set forth herein, contemplated by, or underlying the forward-looking statements.  Investors are cautioned not to place undue reliance on these forward-looking statements, which are valid only as of the date they were made.

The information herein is subject to change without notice. Vital Neuro, Inc. or its affiliates shall not be liable for technical or editorial errors or omissions contained herein.


Vital Neuro, Inc. 
263 W End Ave
New York, NY 10023

CEO: Q Saeed: 303.810.4510